Novel oral anticoagulants and the 73rd anniversary of historical warfarin

Shehab, Abdulla; Elnour, Asim Ahmed; Bhagavathula, Akshaya Srikanth; Erkekoğlu, Pınar; Hamad, Farah; Nuaimi, Saif Al; Shamsi, Ali Al; Mukhtar, Iman; Elrazek, Abd Elrazek M.A. Abd; Suwaidi, Aeshal Al; Mandil, Mahmoud Abu; Baraka, Mohamed; Sadik, Adel; Saraan, Khalid; Kalbani, Naama M.S. Al; Mahmood, Alaa AbdulAziz; Barqawi, Yazan; Hajjar, Mohammed Al; Shehab, Omer Abdulla; Amoodi, Abdulla Al; Abdulla, Rauda; Sanches, Cristina; Shaaban, Zohdi Abu; Eltayeb, Ahmed Eltayeb Yousif Ahmed

doi:10.1016/j.jsha.2015.05.003

Cited by 13 publications

(16 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1] Karl Paul Link, the Wisconsin Alumni Research Fund Scientist (WARF), and his senior student Wilhelm Schoeffel had invented warfarin in 1941, which both gave and took many lives. [1] The drug has celebrated its 75 th birthday this year. It was used as a rodenticide which soon became one of the most prescribed drugs over time.…”

Section: "The Can Of Un-coagulated Blood Lying On the Floor Of Link'smentioning

confidence: 99%

“…It was used as a rodenticide which soon became one of the most prescribed drugs over time. [1] It was used for patients with heart failure and stroke in 1950s, soon employed for various cardiovascular pathologies and cardiovascular prostheses. [1] Warfarin has been a great friend and foe of cardiovascular surgeons, since its advent.…”

Section: "The Can Of Un-coagulated Blood Lying On the Floor Of Link'smentioning

confidence: 99%

See 1 more Smart Citation

Variations in international normalized ratio applications among Turkish cardiovascular surgeons: Daily practice versus Guidelines

Durukan¹

2017

Turk Gogus Kalp Dama

View full text Add to dashboard Cite

Section: "The Can Of Un-coagulated Blood Lying On the Floor Of Link'smentioning

confidence: 99%

Section: "The Can Of Un-coagulated Blood Lying On the Floor Of Link'smentioning

confidence: 99%

Variations in international normalized ratio applications among Turkish cardiovascular surgeons: Daily practice versus Guidelines

Durukan¹

2017

Turk Gogus Kalp Dama

View full text Add to dashboard Cite

“…1 More than 70 years later, this product still remains widely used for the prophylaxis and treatment of venous thrombosis, pulmonary embolism (PE), and thromboembolic complications associated with atrial fibrillation (AF) or cardiac valve replacement. Thrombin and trapped red blood cells are the primary components of venous thrombi, posing serious risks to patients, including a high rate of morbidity and mortality.…”

mentioning

confidence: 99%

“…2 Arterial thrombi, composed of platelets and fibrin, can result in events, including myocardial infarction, stroke, and chronic thromboembolic pulmonary hypertension. 1 In 1955, warfarin was used to treat Dwight Eisenhower after a severe coronary event. 1 However, over the years warfarin has been linked to a wide realm of limitations, including drug-drug interactions, drug-food interactions, the need for frequent monitoring, adverse events, and an increased length of stay in hospitals.…”

mentioning

confidence: 99%

“…1 In 1955, warfarin was used to treat Dwight Eisenhower after a severe coronary event. 1 However, over the years warfarin has been linked to a wide realm of limitations, including drug-drug interactions, drug-food interactions, the need for frequent monitoring, adverse events, and an increased length of stay in hospitals. 1 In an effort to alleviate the stress of these difficulties for patients and physicians, several new oral anticoagulants (NOACs) have been approved.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Edoxaban

Kubli

Snead²,

Cheng-Lai³

2016

Cardiology in Review

View full text Add to dashboard Cite

Warfarin has been a highly prevalent agent for over 70 years; however, its use has been limited by drug-drug interactions, adverse events, and the need for frequent monitoring. To minimize these complications, several non-vitamin K oral anticoagulants have been approved, including the latest agent, edoxaban. Edoxaban is a factor Xa inhibitor approved for the prevention of stroke/systemic embolism in patients with non-valvular atrial fibrillation and for the treatment of venous thromboembolism. Edoxaban was largely studied in the Edoxaban versus Warfarin in Patients with Atrial Fibrillation (ENGAGE AF-TIMI 48) and Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism (Hokusai-VTE) trials, both showing noninferiority when compared with warfarin. Similar to other oral anticoagulants, the most serious adverse effects of edoxaban are related to bleeding. However, there are currently no approved reversal agents. Andexanet alfa and ciraparantag are the latest agents being studied for reversal. This article provides an overview of the safety and efficacy along with the advantages and disadvantages of edoxaban.

show abstract

Safe prescribing of direct oral anticoagulants for non‐valvular AF

Cheong¹,

Ali

2021

Prescriber

View full text Add to dashboard Cite

The use of direct oral anticoagulants (DOACs) is becoming increasingly common in primary care. While this group of drugs requires less intensive monitoring than warfarin, safe prescribing is still necessary to achieve optimum therapeutic effect and minimise adverse effects. This article discusses the key principles of safe DOAC prescribing for non‐valvular atrial fibrillation (NVAF), and the systems that general practices can put in place to achieve this.

show abstract

Novel oral anticoagulants and the 73rd anniversary of historical warfarin

Cited by 13 publications

References 39 publications

Variations in international normalized ratio applications among Turkish cardiovascular surgeons: Daily practice versus Guidelines

Variations in international normalized ratio applications among Turkish cardiovascular surgeons: Daily practice versus Guidelines

Edoxaban

Safe prescribing of direct oral anticoagulants for non‐valvular AF

Contact Info

Product

Resources

About